Stemline Therapeutics: 2Q Earnings Snapshot

August 9, 2018

NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Thursday reported a loss of $18.9 million in its second quarter.

The New York-based company said it had a loss of 66 cents per share.

The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 63 cents per share.

The biopharmaceutical company posted revenue of $500,000 in the period.

Stemline Therapeutics shares have decreased 9 percent since the beginning of the year. The stock has climbed 66 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on STML at https://www.zacks.com/ap/STML

All contents © copyright 2019 The Associated Press.All rights reserved.